Pricing Log in Create free account

Cogent Biosciences, Inc. (COGT) vs Immunovant, Inc. (IMVT)

Cogent Biosciences, Inc. and Immunovant, Inc. are both Biotechnology companies. Immunovant, Inc. is the larger, with a market value of $5.7B against $5.1B — 1.1× the size. Across the 9 metrics below, Immunovant, Inc. leads on 5 and Cogent Biosciences, Inc. on 4.

Valuation

Metric COGT IMVT Biotechnology median
P/E n/m n/m 8.50
P/S 217.97 n/m 9.71
P/B 10.79 7.47 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 193.41 n/m 9.21
Earnings yield (7.32%) (10.55%) (33.15%)
Free cash flow yield (6.13%) (7.55%) (25.50%)

Profitability

Metric COGT IMVT Biotechnology median
Gross margin 0.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (146.55%) (80.10%) (56.36%)
Return on assets (68.00%) (71.10%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric COGT IMVT Biotechnology median
Revenue growth (TTM) 110.23% — 6.02%
EPS growth (last fiscal year) (11.34%) (1.47%) 30.26%
Revenue growth, 5-year CAGR 21.39% — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric COGT IMVT Biotechnology median
Debt to equity 0.42 0.00 0.00
Current ratio 13.57 7.27 4.72
Net debt to EBITDA 2.04 1.69 0.96

Dividend

Metric COGT IMVT Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric COGT IMVT Biotechnology median
Market cap 5.12b 5.68b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack